$GOAI
Eva Live Inc

2024 Q3 Form 10-Q Financial Statement

#000149315224030898 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $1.982M $2.189M $1.080M
YoY Change 16.66% 102.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.496M $2.542M $599.1K
YoY Change 519.91% 324.36%
Operating Profit -$5.514M -$353.9K $480.5K
YoY Change -1225.25% -173.64%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$15.88K -$6.479K
YoY Change
Pretax Income -$5.529M -$360.4K $480.5K
YoY Change -1228.49% -174.99%
Income Tax
% Of Pretax Income
Net Earnings -$5.529M -$360.4K $480.5K
YoY Change -1228.49% -174.99%
Net Earnings / Revenue -278.95% -16.47% 44.51%
Basic Earnings Per Share -$0.04 $0.00 $0.00
Diluted Earnings Per Share -$0.04 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 123.1M shares 123.1M shares 115.6M shares
Diluted Shares Outstanding 124.8M shares 123.1M shares 115.6M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $849.3K $1.338M $23.73K
Short-Term Investments
Other Short-Term Assets $269.00 $269.00
YoY Change
Inventory
Prepaid Expenses
Receivables $1.787M $1.248M
Other Receivables
Total Short-Term Assets $2.637M $2.586M
YoY Change 76.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $2.011M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $60.00K $2.011M
YoY Change -97.06%
TOTAL ASSETS
Total Short-Term Assets $2.637M $2.586M
Total Long-Term Assets $60.00K $2.011M
Total Assets $2.697M $4.597M
YoY Change -23.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.496M $2.314M
YoY Change 27.55%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.496M $2.314M
Total Long-Term Liabilities
Total Liabilities $2.896M $2.818M
YoY Change 44.97%
SHAREHOLDERS EQUITY
Retained Earnings -$29.82M -$24.35M
YoY Change 72.71%
Common Stock $12.50K $12.31K
YoY Change 7.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$199.3K $1.779M $1.043M
YoY Change
Total Liabilities & Shareholders Equity $2.697M $4.597M
YoY Change -23.63%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.529M -$360.4K $480.5K
YoY Change -1228.49% -174.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001983736
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
GOAI Increase Decrease In Payroll Liabilities
IncreaseDecreaseInPayrollLiabilities
usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
GOAI Proceeds From Funds From Promissory Note
ProceedsFromFundsFromPromissoryNote
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
usd
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
usd
CY2024Q2 us-gaap Goodwill
Goodwill
2010606 usd
CY2023Q4 us-gaap Goodwill
Goodwill
2010606 usd
CY2024Q2 us-gaap Assets
Assets
4596852 usd
CY2023Q4 us-gaap Assets
Assets
4078302 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
120000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
108622 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
150000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
240000 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2604 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2313732 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2128837 usd
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
500000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
3875 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1779245 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1949465 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-360361 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1779245 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
670937 usd
us-gaap Net Income Loss
NetIncomeLoss
372412 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1043349 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1949465 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1949465 usd
us-gaap Net Income Loss
NetIncomeLoss
-170220 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1779245 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1779245 usd
us-gaap Net Income Loss
NetIncomeLoss
-170220 usd
us-gaap Net Income Loss
NetIncomeLoss
372412 usd
us-gaap Depreciation
Depreciation
108889 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-347188 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
642148 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-150000 usd
GOAI Increase Decrease In Payroll Liabilities
IncreaseDecreaseInPayrollLiabilities
167500 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11378 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
189487 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-86587 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-43413 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
6479 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
125738 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14773 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
240000 usd
GOAI Proceeds From Funds From Promissory Note
ProceedsFromFundsFromPromissoryNote
500000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
740000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
865738 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14773 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
472509 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38506 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1338247 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23733 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zBW9AbKGGsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zpV4kAnPi62a">Financial Statement Preparation and Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash
Cash
1338247 usd
CY2023Q4 us-gaap Cash
Cash
472509 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
624898 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
624898 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5064 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
27437 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_znJeXvrTBEC4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zzwo46ZehQ31">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash. The Company places its Cash with a major banking institution. The Company did not have cash balances over the Federal Deposit Insurance Corporation limit on June 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
123052349 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123052349 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123052349 shares
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
123052349 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123052349 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123052349 shares
us-gaap Net Income Loss
NetIncomeLoss
-170220 usd
us-gaap Net Income Loss
NetIncomeLoss
372412 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24346311 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24176091 usd
us-gaap Net Income Loss
NetIncomeLoss
-170220 usd
us-gaap Net Income Loss
NetIncomeLoss
372412 usd
CY2024Q2 GOAI Working Capital
WorkingCapital
272514 usd
CY2023Q4 GOAI Working Capital
WorkingCapital
61141 usd
CY2024Q2 us-gaap Cash
Cash
1338247 usd
CY2023Q4 us-gaap Cash
Cash
472509 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
778783 usd
CY2023Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
778783 usd
GOAI Media Traffic Purchase
MediaTrafficPurchase
3616019 usd
GOAI Media Traffic Purchase
MediaTrafficPurchase
601172 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123052349 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123052349 shares

Files In Submission

Name View Source Status
0001493152-24-030898-index-headers.html Edgar Link pending
0001493152-24-030898-index.html Edgar Link pending
0001493152-24-030898.txt Edgar Link pending
0001493152-24-030898-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
goai-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
goai-20240630_cal.xml Edgar Link unprocessable
goai-20240630_def.xml Edgar Link unprocessable
goai-20240630_lab.xml Edgar Link unprocessable
goai-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed